Disposition of 16050 shares by Raymond Stevens of Structure Therapeutics at 6.8366 subject to Rule 16b-3
| GPCR Stock | 34.17 1.13 3.20% |
Slightly above 62% of Structure Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Structure Therapeutics American suggests that many traders are alarmed. Structure Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Structure Therapeutics American. Many technical investors use Structure Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Structure | Build AI portfolio with Structure Stock |
Filed transaction by Structure Therapeutics American Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Structure Therapeutics Fundamental Analysis
We analyze Structure Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Structure Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Structure Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Structure Therapeutics is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Structure Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Structure Therapeutics stock to make a market-neutral strategy. Peer analysis of Structure Therapeutics could also be used in its relative valuation, which is a method of valuing Structure Therapeutics by comparing valuation metrics with similar companies.
Peers
Structure Therapeutics Related Equities
| PDS | Precision Drilling | 2.43 | ||||
| TSEM | Tower Semiconductor | 2.03 | ||||
| ON | ON Semiconductor | 1.94 | ||||
| SDSDF | SD Standard | 0.00 |
Additional Tools for Structure Stock Analysis
When running Structure Therapeutics' price analysis, check to measure Structure Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Structure Therapeutics is operating at the current time. Most of Structure Therapeutics' value examination focuses on studying past and present price action to predict the probability of Structure Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Structure Therapeutics' price. Additionally, you may evaluate how the addition of Structure Therapeutics to your portfolios can decrease your overall portfolio volatility.